Log in Sign up free
40LOW

TLX

TELIXPHARM FPO [TLX]
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Healthcare · ASX Small Cap
$12.3900 +5.9%

Updated 19 Mar 2026 · Scores refresh every scan

Appeared in 2 consecutive scans→ Score +0First seen: 2026-02-25

Score Breakdown

Technical68
Catalyst81
Sentiment50
Fundamental98
Momentum41
Risk Gate48

Active Signals

Bullish Signals

  • MACD momentum is picking up steam
  • Pressing against the upper Bollinger Band — extended and may need to cool off
  • Trading above both moving averages — the trend is your friend here
  • Just broke above 20-day resistance — a level that was capping price, now cleared
  • On a tear — up 10.3% over the last 5 days
  • Beating the Small Ords index — relative strength of 1.47, so it's outpacing the pack
  • Strong cash runway (33 quarters)
  • Low P/S ratio (4.9x)
  • Strong revenue growth (+49%)
  • EPS estimates revised upward (+10pts)
  • Near 52-week low (16% of range)
  • New substantial holder(s) (2)
  • Very high short interest (15.1%)
  • CANSLIM I: Institutional ownership (21%)
  • Sentiment is mixed — no strong consensus either way
  • This one has been in freefall — down 64% over the past year
  • Revenue growing at +49% — the top line is moving in the right direction
  • The bigger volume days are the up days — volume-weighted momentum is positive (0.42%/day)
  • Days to cover very high (14.8)
  • Short squeeze potential (15.1% short + catalyst + momentum)
  • Beneish M-Score -1.68 > -1.78: likely earnings manipulation
  • RBA hiking (-3pts)

Risk Signals

  • Stochastic is stretched into overbought — could need a breather
  • Below the 200-day average — the long-term trend is still working against it
  • Negative profit margins (-1%)
  • Not enough chatter to gauge sentiment — defaulting to neutral

Recent Catalysts

NONE Appendix 3Y Change in Director Interests - C Behrenbruch
NONE Notification of cessation of securities - TLX
NONE Telix Resubmits NDA to FDA for Pixclara Brain Cancer Imaging
HIGH Becoming a substantial holder
HIGH Becoming a substantial holder from CGF

Recent ASX Announcements

2026-03-17 Appendix 3Y Change in Director Interests - C Behrenbruch
2026-03-17 Notification of cessation of securities - TLX
2026-03-17 Becoming a substantial holder
2026-03-15 Telix Resubmits NDA to FDA for Pixclara Brain Cancer Imaging PRICE SENSITIVE
2026-03-12 Becoming a substantial holder from CGF

Key Metrics

$4.0B
Market Cap
3.4M
Avg Volume
0.9x
Vol Ratio
$8.26 — $29.72
52-Week Range
15.1%
Short Interest
N/A
Cash Runway
-1.9%
ROE
-0.9%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 80%
LLeader vs LaggardpassRS: 2
IInstitutional SponsorshippassInst: 21%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #28 of 118 · Sector avg: 37

View all Healthcare signals →
Related Tickers
NAN 56DOC 55CUV 52NSB 51PNV 49

Sign up free to unlock TLX analysis

Score breakdowns, signals, catalysts, and full analysis for 2,200+ ASX small caps. 30-day free Pro trial included.

No credit card required. Unsubscribe anytime.
Already have access? Log in